EP1521588A2 - Utilisation d'inhibiteurs des alanyl-aminopeptidases et preparations pharmaceutiques contenant ces derniers - Google Patents

Utilisation d'inhibiteurs des alanyl-aminopeptidases et preparations pharmaceutiques contenant ces derniers

Info

Publication number
EP1521588A2
EP1521588A2 EP03762633A EP03762633A EP1521588A2 EP 1521588 A2 EP1521588 A2 EP 1521588A2 EP 03762633 A EP03762633 A EP 03762633A EP 03762633 A EP03762633 A EP 03762633A EP 1521588 A2 EP1521588 A2 EP 1521588A2
Authority
EP
European Patent Office
Prior art keywords
inhibitors
use according
same substrate
substrate specificity
paq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03762633A
Other languages
German (de)
English (en)
Inventor
Siegfried Ansorge
Janine Tadje
Uwe Lendeckel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IMTM GmbH
Original Assignee
IMTM GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IMTM GmbH filed Critical IMTM GmbH
Priority to EP09160281A priority Critical patent/EP2085094A2/fr
Publication of EP1521588A2 publication Critical patent/EP1521588A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • inhibitors of alanyl aminopeptidases Use of inhibitors of alanyl aminopeptidases and pharmaceutical compositions comprising them
  • the present invention relates to the use of one or more inhibitors of alanyl aminopeptidases and / or of enzymes of the same substrate specificity for inducing the production of TGF- ⁇ 1 and expression of TGF- ⁇ 1 in and / or on Treg cells and the use for the prevention and / or treatment of autoimmune diseases, allergies, arteriosclerosis and for the suppression of graft rejection.
  • the invention further relates to uses in which peptide fragments of pathogenic autoantigens or synthetic analogs and / or specific antigenic components of pathogenic microorganisms are additionally used.
  • the joint application of inhibitors against the above-mentioned enzymes with disease-specific antigens enhances the targeted action of the inhibitors against pathogenic T-cell clones and is suitable for the specific therapy of immunologically related diseases.
  • Fig. 5 The inhibition of autoreactive T cells via soluble (a) or membrane-bound TGF-ßl (b) is shown schematically in Fig. 5.
  • the membrane-bound TGF-ßl on Treg has a direct inhibitory effect on autoreactive T cells by binding to their TGF-ßl receptor (cell-cell contact), which can be seen in Fig. 5 (b) above.
  • This cell contact can be achieved through the simultaneous binding of both Treg and autoreactive T cells to an antigen-presenting cell (APC, in particular dendritic cells).
  • APC antigen-presenting cell
  • previous binding of the Treg to the APC can change it (lack of costimulatory signals) so that a subsequently binding autoreactive T cell is not activated (anergy).
  • the Treg and autoreactive T cell are characterized by the same antigen specificity.
  • Treg natural regulatory T cells
  • Treg cells arise in the thymus [Kawahata K. et al., J. Immunol. 168: 4399-4405, 2002] and account for 5-10% of the T cells in peripheral blood. They have an inhibitory effect on CD4 + T cells of the same antigen specificity via direct cell contact. This inhibitory effect is shown by a strong expression of TGF-ßl in the Treg reached.
  • the TGF-ßl is presented on the surface of the Treg and binds to the TGF-ßl receptor on autoreactive T cells, which represents a completely new mechanism of action of this strong immunosuppressive cytokine [Nakamura et al., J Exp Med 194: 629- 644, 2001].
  • Treg cells inhibit autoimmunity more efficiently than the immune response to "foreign" antigens [Romagnoli P et al., J hnmunol 168: 1644-1648, 2002]. Therefore, restrictions or losses in the functioning of Treg cells are of particular pathogenetic importance in the development of autoimmune disorders.
  • a direct relationship between the number / function of Treg cells and the manifestation of autoimmune diseases is for type I diabetes [Boudaly S et al., Eur Cytokine Netw 13: 29-37, 2002; Gregori S et al., Diabetes 51: 1367-1374, 2002], autoimmune encephalomyelitis (animal model of multiple sclerosis) [Furtado GC et al., Hnmunol Rev 182: 122-134, 2001; Muhallab S et al., Scand J Hnmunol 55: 264-273, 2002; Hamilton NH et al., Scand J hnmunol 55: 171-177, 2002], for the "autoimmune ovarian disease" (AOD) [Tung KS et al., Hnmunol Rev 182: 135- 148, 2001], and for the disease Crohn [Neurath MF et al., J Exp Med 195: 1129-1143, 2002].
  • Treg cells are also responsible for suppressing intestinal or pulmonary inflammation [Singh B et al., Hnmunol Rev 182: 190-200, 2001; Hori S et al., Eur J Hnmunol 32: 1282-1291, 2002].
  • the role of Treg cells in suppressing rejection episodes after allogeneic (foreign) organ transplantation is also clearly demonstrated [Kingsley CI et al., J hnmunol 168: 1080-1086, 2002; Taylor PA et al., Blood 99: 3493-3499, 2002; Chiffoleau E et al., Jnnmunol 168: 5058-5069, 2002].
  • each Treg cell clone is directed against a specific antibody and inhibits autoreactive T cells of the same antigen specificity under normal physiological conditions, in the case of Autoimmune diseases lose this Treg function and auto-reactive T cell clones, such as those used in type I diabetes against proteins of the pancreatic beta cell, lead to the outbreak of the autoimmune disease.
  • this antigen specificity can also be used therapeutically, by increasing or increasing the number / function of these cells through targeted "antigen-specific" activation in vivo or ex vivo of Treg cells (or of denritic cells activating these cells) getting produced.
  • TGF-ßl for the regulation of immunological hyperreactivity
  • two recent publications show that the overproduction of TGF-ßl in CD4 + cells caused by genetic manipulation can suppress the disease process.
  • Th2 cells are crucially involved in the pathogenesis, the function of pathogenic Th2 cell clones can accordingly be effectively inhibited by transgenic overproduction of TGF- ⁇ 1 [Hansen G et al., J Clin ivest 105: 61-70 , 2000; Thorbecke GJ et al., Cytokine Growth Factor Rev 11: 89-96, 2000].
  • the present invention has for its object to provide an efficient method for the induction of production and expression of TGF-ßl in and / or on Treg cells, which is also for the prevention and / or treatment of autoimmune diseases, allergies, arteriosclerosis and the suppression of Graft rejection on humans or animals is suitable. Another object is to provide corresponding pharmaceutical preparations with which these objects can be achieved.
  • inhibitors of alanyl aminopeptidases and / or of enzymes of the same substrate specificity induce the production of TGF-ßl and expression of TGF-ßl in and / or on Treg cells and thus for the prevention and treatment of Autoimmune diseases, allergies and arteriosclerosis are suitable and can serve to suppress transplant rejections.
  • the invention therefore relates to the use of one or more inhibitors of alanyl aminopeptidases and / or of enzymes of the same substrate specificity for inducing the production of TGF- ⁇ 1 and expression of TGF- ⁇ 1 in and / or on Treg cells.
  • inhibitors of alanyl aminopeptidases and all inhibitors of enzymes of the same substrate specificity come into consideration as inhibitors.
  • ⁇ -ketoamides particularly preferred among these are ⁇ -ketoamides, ⁇ -aminophosphinic acids, N-phenylhomophthalimides, ⁇ -aminophosphonates and phebestin, 3-amino-2-oxo-4-phenylbutanoic acid amides being particularly preferred as ⁇ -ketoamides, D-Phe- as ⁇ -aminophosphinic acids ⁇ [PO (OH) -CH 2 ] -Phe-Phe, as N-phenylhomophthalimide PAQ-22, as ⁇ -aminophosphonates RB3014 and / or phebestin, and very particularly preferably PAQ-22, RB3014 and / or phebestin.
  • cytosolic alanyl aminopeptidase As an enzyme with the same substrate specificity as the alanyl aminopeptidases, cytosolic alanyl aminopeptidase may be mentioned here by way of example.
  • PAQ-22 is specific for the cytosolic alanyl aminopeptidase.
  • As a preferred inhibitor of the cytosolic alanyl Aminopeptidase is therefore used PAQ-22, or a mixture of several inhibitors comprising PAQ-22.
  • the inhibition of the enzymatic activity of the membrane-bound alanyl aminopeptidase increases the gene expression of TGF-ßl in Treg cells and the expression of the immunosuppressive cytokm TGF-ßl ("transforming growth factor ßl") in / on regulatory cells.
  • TGF-ßl selectively strengthens or restitutes the function of Treg cells and is due to the above-mentioned relationships between the expression of TGF-ßl on the Treg cells and the inhibitory effect on autoreactive T-lymphocytes are suitable to overcome the functional deficits of Treg cells existing in autoimmune diseases and inflammatory diseases, in allergies and in rejection episodes after organ transplantation and thus to allow the prevention of these diseases and / or to improve the course or the severity of these diseases and / or cure these diseases. All of these diseases and the rejection episodes after organ transplantation are due to the lack of a sufficiently effective natural immunosuppressive principle, i.e. H. insufficiently functioning immunoregulatory cells, including deficient production of TGF-ßl.
  • the induction of TGF- ⁇ 1 according to the invention is not restricted to individual antigen-specific T cell clones.
  • the invention therefore also relates to the use of one or more inhibitors of alanyl aminopeptidases and / or of enzymes of the same substrate specificity for the prevention and / or treatment of autoimmune disorders.
  • the use according to the invention is preferred for the prevention and / or treatment of rheumatoid arthritis, lupus erythematosus, multiple sclerosis, IDDM, Crohn's disease, ulcerative colitis, psoriasis, neurodermatitis, glomerulonephritis, interstitial nephritis, vasculitis, autoimmune ScMeldhdäfflemischendiseases chronic anemia, autoimmune diseases with an inflammatory genesis such as arteriosclerosis.
  • an inhibitor or several inhibitors of alanyl aminopeptidases and / or of enzymes of the same substrate specificity are also used for the prevention and / or treatment of type I allergies according to Gell and Coombs or allergies of the type ⁇ , HI or IV.
  • the use for the prevention and / or treatment of bronchial asthma or hay fever as type I allergy according to Gell and Coombs and / or contact allergies as type ⁇ , DI or IV allergies is preferred.
  • the invention further relates to the use of one or more inhibitors of alanyl aminopeptidases and / or of enzymes of the same substrate specificity for suppressing graft rejection, preferably in kidney or bone marrow transplants.
  • inhibitors of alanyl aminopeptidases and all inhibitors of enzymes of the same substrate specificity come into consideration as inhibitors.
  • Preferred are actinonin, leuhistin, phebestin, amastatin, bestatin, probestin, arphamenin, MR 387, ⁇ -aminothiols, ⁇ -aminophosphinic acids and their esters and salts, ⁇ -aminophosphonates, ⁇ -aminoboronic acids, ⁇ -aminoaldehydes, hydroxamates of ⁇ -amino acids, N-phenylphthalimide, N-phenylhomophthalimide, ⁇ -ketoamides, thalidomide and their derivatives are used.
  • ⁇ -ketoamides, ⁇ -aminophosphinic acids, N-phenylhomophthalimides, ⁇ -aminophosphonates and phebestin are particularly preferred, 3-amino-2-oxo-4-phenylbutanoic acid amides being particularly preferred as ⁇ -ketoamides, D-Phe- as ⁇ -aminophosphinic acids ⁇ [PO (OH) -CH 2 ] -Phe-Phe, as N-phenylhomophthalimide PAQ-22, as ⁇ -aminophosphonates RB3014 and / or phebestin, and very particularly preferably PAQ-22, RB3014 and / or phebestin
  • cytosolic alanyl aminopeptidase As an enzyme with the same substrate specificity as the alanyl aminopeptidases, cytosolic alanyl aminopeptidase may be mentioned here by way of example.
  • PAQ-22 is specific for the cytosolic alanyl aminopeptidase.
  • As a preferred inhibitor of the cytosolic alanyl Aminopeptidase is therefore used PAQ-22, or a mixture of several inhibitors comprising PAQ-22.
  • the invention therefore also relates to the use of inhibitors of alanyl aminopeptidases and / or of enzymes of the same substrate specificity for the induction of production of TGF- ⁇ 1 and expression of TGF- ⁇ 1 in and / or on Treg cells and for the prevention and / or treatment of Autoimmune diseases, allergies, hay fever, arteriosclerosis and to suppress transplant rejection, in which peptide fragments of pathogenic autoantigens or synthetic analogues and / or specific antigenic components of pathogenic microorganisms are additionally used.
  • peptide fragments of pathogenic autoantigens or synthetic analogs and / or specific antigenic components of pathogenic microorganisms are additionally used.
  • Preferred peptide fragments of pathogenic autoantigens in multiple sclerosis are MBP (myelin basic protein), MOG (myelin oligodendrocyte glycoprotein), MAG (myelin associated glycoprotein) and PLP (proteolipid protein), preferred specific antigenic components of pathogenic microorganisms are coat proteins or membrane glycolipid complexes.
  • the invention therefore also relates to the use of one or more inhibitors of alanyl aminopeptidases and / or of enzymes of the same substrate specificity for the manufacture of a medicament or a pharmaceutical preparation for inducing the production of TGF-ßl and expression of TGF-ßl in and / or on Treg cells.
  • inhibitors of alanyl aminopeptidases and all inhibitors of enzymes of the same substrate specificity come into consideration as inhibitors. Actinonine, leuhistine, phebestine, amastatin, bestatin, probestin, arphamenine, MR 387, ⁇ -aminothiols, ⁇ -aminophosphinic acids and their esters and salts, ⁇ -aminophosphonates, ⁇ -aminoboronic acids, ⁇ -aminoaldehydes, hydroxamates of ⁇ -amino acids are preferred. N-phenylphthalimide, N-phenylhomophthalimide, ⁇ -ketoamides, thalidomide and their derivatives are used.
  • ⁇ -ketoamides particularly preferred among these are ⁇ -ketoamides, ⁇ -aminophosphinic acids, N-phenylhomophthalimides, ⁇ -aminophosphonates and phebestin, 3-amino-2-oxo-4-phenylbutanoic acid amides being particularly preferred as ⁇ -ketoamides, D-Phe- as ⁇ -aminophosphinic acids ⁇ [PO (OH) -CH 2 ] -Phe-Phe, as N-phenylhomophthalimide PAQ-22, as ⁇ -aminophosphonates RB3014 and / or phebestin, and very particularly preferably PAQ-22, RB3014 and / or phebestin.
  • cytosolic alanyl aminopeptidase As an enzyme with the same substrate specificity as the alanyl aminopeptidases, cytosolic alanyl aminopeptidase may be mentioned here by way of example.
  • PAQ-22 is specific for the cytosolic alanyl aminopeptidase. PAQ-22 is therefore used as the preferred inhibitor of cytosolic alanyl aminopeptidase, or a mixture of several inhibitors comprising PAQ-22 is used.
  • the invention also relates to the use of an inhibitor or several inhibitors of alanyl aminopeptidases and / or of enzymes of the same substrate specificity for the production of a medicament or a pharmaceutical preparation for the prevention and / or treatment of autoimmune disorders, of type I allergies according to Gell and Coombs, such as hay fever, ⁇ , HI or IV type allergies and the use in the manufacture of a medicament or a pharmaceutical preparation for suppressing transplant rejection.
  • Preferred diseases and types of transplantation are listed in subclaims 26, 27, 29 and 31.
  • Preferred inhibitors of alanyl aminopeptidases and enzymes of the same substrate specificity are mentioned in claims 32 to 35.
  • peptide fragments of pathogenic autoantigens in multiple sclerosis or synthetic analogues and / or specific antigenic components of pathogenic microorganisms may additionally be used, MBP (myelin basic protein), MOG (myelin oligodendrocyte glycoprotein), MAG (myelin associated glycoprotein) and / or PLP (proteolipid protein) and / or as specific antigenic components are more pathogenic as preferred peptide fragments of pathogenic autoantigens
  • MBP myelin basic protein
  • MOG myelin oligodendrocyte glycoprotein
  • MAG myelin associated glycoprotein
  • PLP proteolipid protein
  • the present invention relates to a pharmaceutical preparation comprising an inhibitor or more inhibitors of alanyl aminopeptidases and / or enzymes of the same substrate specificity and one or more pharmacologically acceptable carriers, additives and / or auxiliaries.
  • the invention also relates to a pharmaceutical preparation containing an inhibitor or several inhibitors of alanyl aminopeptidases and / or enzymes of the same substrate specificity and peptide fragments of pathogenic autoantigens or synthetic analogs and / or specific antigenic components of pathogenic microorganisms, and one or more pharmacologically acceptable carriers, additives - And / or auxiliary substances.
  • the invention shows that for the treatment of inflammatory diseases and autoimmune diseases as well as allogeneic rejection reactions and allergies, for the development of which the proliferation and activation of pathogenic T cell clones play a central role, the application of inhibitors of the abovementioned enzymes or appropriate preparations and dosage forms are suitable.
  • the simultaneous application of disease-specific antigens further increases this therapeutic effect and narrows the effect on the pathogenetically relevant process.
  • the application of aminopeptidase inhibitors to induce TGF- ⁇ 1 expression in / on Treg cells and thus to increase the immunosuppressive function of this pathogenetically important inhibitory T cell population provides a novel method for the diseases mentioned and a supplementary one in the central one is a form of therapy that intervenes.
  • inhibitors of alanyl aminopeptidases and / or of enzymes of the same substrate specificity can be used in pharmaceutically acceptable formulation complexes as inhibitors, substrates, pseudo-substrates, inhibitory peptides and peptide derivatives and as antibodies of this enzyme.
  • Preferred inhibitors are Bestaun, Phebestin, Probestin, Actinonin, Leuhistin, RB3014, PAQ-22 and their derivatives, Phebestin, RB3014 and / or PAQ-22 are particularly preferred.
  • the administration can take place in all suitable forms, for example as a topical application in the form of creams, ointments, pastes, gels, solutions, sprays, liposomes, shaking mixtures, hydrocolloid dressings or other dermatological bases / vehicles including instillative application or as a systemic application oral, transdermal, intravenous, subcutaneous, intracutaneous, inhalative, intramuscular use in suitable formulations or in suitable galenics or in connection with or incorporation into microparticles to overcome the blood-brain barrier.
  • the application of "disease-specific" antigens petid fragments, lipopolysaccharides, etc.
  • in appropriate dosage forms can increase the success of the therapy.
  • TGF- / 31 human regulatory T lymphocytes (CD4 + CD25 + ) after incubation with the inhibitor phebestin.
  • the T cells were incubated with phebestin for 24 hours without addition (control), with addition of PHA and PMA and with simultaneous addition of PHA / PMA.
  • PHA phythema agglutinin
  • PMA phorbol myristate acetate
  • the surface expression of TGF-ßl was then measured using flow cytometry using the commercially available polyclonal anon-TGF-ßl antibody (chicken anti-human; R&D Systems). The results are shown in Figure 1.
  • T cells were incubated for 24 hours without addition (control), with addition of PHA and PMA or with simultaneous addition of PHA PMA with phebestin.
  • PHA phytoaddition factor
  • PMA phorbol myristate acetate
  • the content of TGF / 31 mRNA was then determined by means of quantitative RT-PCR using the i-cycler. The results are shown in Figure 2.
  • T cells were incubated with PAQ-22 for 24 hours without addition (control), with addition of PHA and PMA or with simultaneous addition of PHA / PMA.
  • PHA phytoaddition factor
  • PMA phorbol myristate acetate
  • T cells were incubated with RB3014 for 72 hours without addition (control), with addition of PHA and PMA or with simultaneous addition of PHA / PMA.
  • PHA phytoaddition factor
  • PMA phorbol myristate acetate
  • the content of TGF- ⁇ 1 mRNA was then determined by means of quantitative RT-PCR using the i-cycler. The results are shown in Figure 4.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne l'utilisation d'un ou de plusieurs inhibiteurs des alanyl-aminopeptidases et/ou d'enzymes présentant la même spécificité de substrat pour induire la production de TGF-ss 1 et l'expression de TGF-ss 1 dans et/ou sur des lymphocytes T régulateurs. L'invention concerne également l'utilisation de ces inhibiteurs pour la prévention et/ou le traitement de maladies auto-immunes, d'allergies, de l'artériosclérose, et pour empêcher les rejets de greffons. L'invention concerne en outre des utilisations desdits inhibiteurs, faisant appel en outre à des fragments peptidiques d'auto-antigènes pathogènes ou d'analogues de synthèse et/ou de composants antigéniques spécifiques de micro-organismes pathogènes.
EP03762633A 2002-07-05 2003-07-04 Utilisation d'inhibiteurs des alanyl-aminopeptidases et preparations pharmaceutiques contenant ces derniers Withdrawn EP1521588A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09160281A EP2085094A2 (fr) 2002-07-05 2003-07-04 Utilisation d'inhibiteurs des alanyl-aminopeptidases et préparations pharmaceutiques en étant pourvues

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10230381 2002-07-05
DE10230381A DE10230381A1 (de) 2002-07-05 2002-07-05 Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen
PCT/EP2003/007199 WO2004004750A2 (fr) 2002-07-05 2003-07-04 Utilisation d'inhibiteurs des alanyl-aminopeptidases et preparations pharmaceutiques contenant ces derniers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP09160281A Division EP2085094A2 (fr) 2002-07-05 2003-07-04 Utilisation d'inhibiteurs des alanyl-aminopeptidases et préparations pharmaceutiques en étant pourvues

Publications (1)

Publication Number Publication Date
EP1521588A2 true EP1521588A2 (fr) 2005-04-13

Family

ID=29761689

Family Applications (2)

Application Number Title Priority Date Filing Date
EP09160281A Withdrawn EP2085094A2 (fr) 2002-07-05 2003-07-04 Utilisation d'inhibiteurs des alanyl-aminopeptidases et préparations pharmaceutiques en étant pourvues
EP03762633A Withdrawn EP1521588A2 (fr) 2002-07-05 2003-07-04 Utilisation d'inhibiteurs des alanyl-aminopeptidases et preparations pharmaceutiques contenant ces derniers

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP09160281A Withdrawn EP2085094A2 (fr) 2002-07-05 2003-07-04 Utilisation d'inhibiteurs des alanyl-aminopeptidases et préparations pharmaceutiques en étant pourvues

Country Status (9)

Country Link
US (1) US7425532B2 (fr)
EP (2) EP2085094A2 (fr)
JP (1) JP2005532380A (fr)
CN (1) CN1665524B (fr)
AU (1) AU2003250892B2 (fr)
CA (1) CA2490714A1 (fr)
DE (1) DE10230381A1 (fr)
EA (1) EA008946B1 (fr)
WO (1) WO2004004750A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10348044A1 (de) * 2003-10-15 2005-05-19 Imtm Gmbh Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
DE10348022A1 (de) * 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
DE10348023A1 (de) * 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
US20060063208A1 (en) 2004-08-02 2006-03-23 Woolf Clifford J DRG11-responsive (DRAGON) gene and uses thereof
EP1669086A1 (fr) * 2004-12-09 2006-06-14 Advitech Solutions Inc. Composition contenant du TGF-beta et des protéines pour traiter le psoriasis
US7763257B2 (en) 2004-12-09 2010-07-27 Christina Juneau Compositions comprising transforming growth factor (TGF)-β1 and TGF-β2 in admixture of proteins obtained from dairy products
WO2006088972A2 (fr) 2005-02-16 2006-08-24 The General Hospital Corporation Methodes et compositions pour reguler le metabolisme du fer
EA026578B1 (ru) * 2007-01-22 2017-04-28 ДЖиТиЭкс, ИНК. Вещества, связывающие ядерные рецепторы
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) * 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
ES2308916B1 (es) * 2007-03-22 2009-10-29 Consejo Superior De Investigaciones Cientificas Compuesto inhibidor dual de las enzimas pde7 y/o pde4, composiciones farmaceuticas y sus aplicaciones.
WO2008124768A1 (fr) 2007-04-09 2008-10-16 The General Hospital Corporation Protéines de fusion d'hémojuvéline et utilisations de celles-ci
DE102007039429A1 (de) * 2007-08-21 2009-02-26 Imtm Gmbh Verfahren zur Aktivierung regulatorischer T-Zellen
JP6018753B2 (ja) 2008-11-13 2016-11-02 ザ・ジェネラル・ホスピタル・コーポレイションＴｈｅ Ｇｅｎｅｒａｌ Ｈｏｓｐｉｔａｌ Ｃｏｒｐｏｒａｔｉｏｎ Ｂｍｐ−６の調節によって鉄の恒常性を制御するための方法および組成物
EP2366394A1 (fr) 2010-03-17 2011-09-21 IMTM GmbH Caractérisation et validation d'inhibiteurs et de ligands de la dipeptidyl-aminopeptidase de type IV (DP IV)
CN102631664B (zh) * 2011-01-28 2014-10-01 上海来益生物药物研究开发中心有限责任公司 3-氨基-2-羟基-4-苯基-缬氨酰-异亮氨酸的应用
US9783616B2 (en) * 2013-04-02 2017-10-10 University Of Connecticut Regulating transplant rejection of donor and embryonic stem cell-derived tissues and organs
WO2017214555A1 (fr) * 2016-06-10 2017-12-14 The Regents Of The University Of Michigan Modulation de l'aminopeptidase n/cd13 et polyarthrite rhumatoïde

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3347531A1 (de) * 1983-12-30 1985-07-11 Basf Ag, 6700 Ludwigshafen Magnetische aufzeichnungstraeger
EP0189569B1 (fr) * 1984-12-22 1989-02-01 EJOT Adolf Böhl GmbH & Co. KG Dispositif de fixation
CA2070281C (fr) 1989-12-20 2005-08-23 David Allen Hafler Traitement ameliore des maladies auto-immunes par administration aerosol d'auto-antigenes
WO1995004533A2 (fr) * 1993-08-04 1995-02-16 Andrulis Pharmaceuticals Corporation Traitement de la polyarthrite rhumatoide par le thalidomide seul ou associe a d'autres anti-inflammatoires
IL115766A0 (en) 1994-10-25 1996-01-19 Immulogic Pharma Corp Composition and treatment for multiple sclerosis
JP3917711B2 (ja) * 1997-05-12 2007-05-23 財団法人微生物化学研究会 フェベスチン誘導体
JP2001131066A (ja) * 1999-08-25 2001-05-15 Nippon Kayaku Co Ltd アポトーシス増強剤
JP2001089360A (ja) * 1999-09-16 2001-04-03 Shionogi & Co Ltd Ｔリンパ球増殖反応の低下剤
DE10002820A1 (de) 2000-01-24 2001-08-23 Walter Schubert Aminopeptidasen-Inhibitor
DE10025464A1 (de) * 2000-05-23 2001-12-06 Inst Medizintechnologie Magdeb Kombinierte Verwendung von Enzyminhibitoren zur Therapie von Autoimmunerkrankungen, bei Transplantationen und Tumorerkrankungen sowie Kombinationen von Enzyminhibitoren umfassende pharmazeutische Zubereitungen
DE10100052A1 (de) * 2001-01-02 2002-07-11 Inst Medizintechnologie Magdeb Kombinierte Verwendung von Enzyminhibitoren und pharmazeutischen Zubereitungen daraus zur Therapie und Prophylaxe der Atheriosklerose
DE10211555A1 (de) * 2002-03-15 2003-10-02 Imtm Inst Fuer Medizintechnolo Verwendung der Inhibitoren von Enzymen mit Aktivitäten der Aminopeptidase N und/oder der Dipeptidylpeptidase IV und pharmazeutischen Zubereitungen daraus zur Therapie und Prävention dermatologischer Erkrankungen mit sebozytärer Hyperproliferation und veränderten Differenzierungszuständen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004004750A2 *

Also Published As

Publication number Publication date
JP2005532380A (ja) 2005-10-27
EA008946B1 (ru) 2007-10-26
CA2490714A1 (fr) 2004-01-15
WO2004004750A3 (fr) 2004-05-06
WO2004004750A2 (fr) 2004-01-15
US20060211602A1 (en) 2006-09-21
EP2085094A2 (fr) 2009-08-05
CN1665524A (zh) 2005-09-07
US7425532B2 (en) 2008-09-16
EA200500163A1 (ru) 2005-08-25
AU2003250892B2 (en) 2006-11-16
AU2003250892A1 (en) 2004-01-23
CN1665524B (zh) 2010-08-25
DE10230381A1 (de) 2004-01-22

Similar Documents

Publication Publication Date Title
EP1521588A2 (fr) Utilisation d'inhibiteurs des alanyl-aminopeptidases et preparations pharmaceutiques contenant ces derniers
DE69132688T2 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE69831971T2 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
DE69332518T2 (de) Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung
DE69837324T2 (de) Behandlung der multiplen sklerose durch einnahme von copolymer-1
DE69830582T2 (de) Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind
WO2009135615A2 (fr) Moyens servant au traitement et/ou à la prophylaxie d'une maladie auto-immune et à la génération de lymphocytes t régulateurs
DE69737065T2 (de) Insulin c-peptide
CN106535907A (zh) 用于治疗或预防代谢疾病的包含作为活性成分的来源于Akkermansia muciniphila菌的胞外囊泡的组合物
US9034826B2 (en) Use of epidermal growth factor for the morphofunctional restoration of peripheral nerves in diabetic neuropathy
EP2790698A1 (fr) Traitement de trouble auto-immun à l'aide d'agonistes rxr
EP2198723B1 (fr) Composés anti-inflammatoires
DE69637104T2 (de) Heilmittel für arthrosis deformans und entzündliche gelenkerkrankungen
DE69031563T2 (de) Behandlung der autoimmunen uveoretinitis in menschen
DE69902127T2 (de) Histon beinhaltende zusammenstellung zur behandlung von rheumatischer arthritis
WO1993006831A1 (fr) Emploi de misoprostol dans le traitement d'allergies
DE69129563T2 (de) Epidermis-Wachstumsfaktor als Arzneimittel zur Wiederherstellung der Neuronen der Substantia nigra in der Behandlung nervenzerstörender Störungen
Boland Clinical use of cortisone, hydrocortisone, and corticotropin
DE4413938A1 (de) Peptide als Therapeutikum für Autoimmunerkrankungen
AU669154B2 (en) Pharmaceutical compositions for the treatment and/or prevention of degenerative disorders in the retina
AU2005276345A1 (en) Use of a fatty acid for preparing a topical composition for allaying inflammatory reactions due to venemous hymenoptera stings
EP4656198A2 (fr) Utilisation de gmi de spores de ganoderma lucidum dans la préparation de produits pharmaceutiques et de produits alimentaires
US11986458B1 (en) Natural and synthetic andrographolides compounds for the treatment of skeletal muscular dystrophies
DE3887137T2 (de) Mittel zur prophylaxe und behandlung einer pankreatischen erkrannkung oder dergleichen.
Shinitzky The lipid regimen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050207

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

GBC Gb: translation of claims filed (gb section 78(7)/1977)
EL Fr: translation of claims filed
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: IMTM GMBH

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20090520